Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to market, The Wall Street Journal said.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top executives met, like they had dozens of times before, to hear the long-awaited results of a study involving a new drug.